US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle
Executive Summary
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
You may also be interested in...
Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
Tuberculosis drug pretomanid gets endorsement, with Phase III trial waiver, from a key expert panel that advises India's drugs regulator, but roll out plan needs to be defined under the country’s national TB program, say health activists.
Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
SK Bioscience First To Line In Korea COVID Vaccine Race
SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.